{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:35:57Z","timestamp":1767854157050,"version":"3.49.0"},"reference-count":33,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.1080\/13696998.2021.1908001","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T07:47:40Z","timestamp":1617176860000},"page":"469-478","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Treatment patterns, healthcare resource utilization, and costs of patients diagnosed with primary mediastinal B-cell lymphoma in the United States"],"prefix":"10.1080","volume":"24","author":[{"given":"Xiaoqin","family":"Yang","sequence":"first","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2601-6214","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Lalibert\u00e9","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Germain","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Raut","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuvayu S.","family":"Sen","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0981-0486","authenticated-orcid":false,"given":"Dominique","family":"Lejeune","sequence":"additional","affiliation":[{"name":"Groupe d\u2019analyse, Lt\u00e9e, Montr\u00e9al, QC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaushal","family":"Desai","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc, Kenilworth, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Armand","sequence":"additional","affiliation":[{"name":"Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,4,13]]},"reference":[{"key":"CIT0001","unstructured":"National Cancer Institute (NCI) Surveillance Epidemiology and End Results Program (SEER). Primary mediastinal (thymic) large B-cell lymphoma 2019. [cited 2019 June 18]. Available from: https:\/\/seer.cancer.gov\/seertools\/hemelymph\/51f6cf56e3e27c3994bd5318\/."},{"key":"CIT0002","volume-title":"World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","volume":"3","author":"Jaffe E","year":"2001"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-326538"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000004054"},{"key":"CIT0005","unstructured":"\u00a9 National Comprehensive Cancer Network Inc. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Guideline Name V.32019. All rights reserved. 2019 [cited February 13, 2020]. Available from: to view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq418"},{"issue":"2","key":"CIT0007","first-page":"187","volume":"86","author":"Zinzani PL","year":"2001","journal-title":"Haematologica"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj030"},{"issue":"12","key":"CIT0009","first-page":"1258","volume":"87","author":"Zinzani PL","year":"2002","journal-title":"Haematologica"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214561"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V106.11.929.929"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1646"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.10.3289.422k32_3289_3293"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1080\/10428190802108870"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1177\/2040620719841591"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.717"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2.1.31"},{"key":"CIT0018","doi-asserted-by":"crossref","unstructured":"Zinzani PL. Nivolumab combined with brentuximab vedotin for relapsed\/refractory primary mediastinal large b-cell lymphoma: efficacy and safety from the phase 2 CheckMate 436 study. 15th International Conference on Malignant Lymphoma; June 18-22, 2019; Lugano, Switzerland 2019.","DOI":"10.1097\/01.HS9.0000564652.16751.86"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0059"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.2217\/lmt.15.12"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2013.19.6.461"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0196007"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.8.2685"},{"key":"CIT0024","first-page":"1","author":"Optum I.","year":"2018","journal-title":"Clinformatics\u00ae Data Mart User Manual"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.publhealth.20.1.125"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15051"},{"issue":"3","key":"CIT0027","first-page":"283","volume":"369","author":"Wilson WH","year":"2013","journal-title":"N Engl J Med"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.5.804"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.7.1336"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05661.x"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198910000-00013"},{"key":"CIT0032","unstructured":"YESCARTA\u00ae (axicabtagene ciloleucel) highlights of prescribing information. Kite Pharma, Inc. 2019."},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2017.01.009"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2021.1908001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T12:37:20Z","timestamp":1641386240000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2021.1908001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1,1]]}},"alternative-id":["10.1080\/13696998.2021.1908001"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2021.1908001","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-12-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}